Forget Bristol-Myers: Regeneron takes on Merck for the heavyweight title in non-small cell lung cancer

Regeneron may have been the 6th biopharma company to land an initial approval for a PD-1/L1 therapy, but they’re clearly not settling for anything close to a last-place finish in the amazing race for market dominance in the mega-blockbuster field.